Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 14/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27440630 | 0.87 | MEN1 (0.64) | KMT2AKDM4ENPSR1MEN1NLRP3 | |
| SCHEMBL27440624 | 0.85 | PTGES (0.68) | PTGESKMT2AKDM4EHPGDNPSR1 | |
| SCHEMBL22260247 | 0.81 | PTGES (0.73) | PTGESKMT2AKDM4EHPGDNPSR1 | |
| SCHEMBL11245208 | 0.81 | KMT2A (0.72) | PTGESKMT2AKDM4EHPGDNPSR1 | |
| SCHEMBL22260230 | 0.79 | PTGES (1.00) | PTGESKMT2AKDM4EHPGDNPSR1 | |
| SCHEMBL22260246 | 0.79 | PTGES (0.70) | PTGESKMT2AKDM4EHPGDNPSR1 | |
| SCHEMBL22259998 | 0.79 | PTGES (0.70) | PTGESKMT2AKDM4EHPGDNPSR1 | |
| SCHEMBL27440650 | 0.78 | PTGES (0.51) | PTGESKMT2AMEN1NLRP3 | |
| SCHEMBL22260235 | 0.77 | PTGES (1.00) | PTGESKMT2AKDM4EHPGDNPSR1 | |
| SCHEMBL14133150 | 0.77 | PTGES (0.70) | PTGESKMT2AKDM4EHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030877-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2024-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030877-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | PTGES, PTGS1, PTGES2 | PTGES 1/4885KMT2A 4205/4885KDM4E 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.